Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism

Clinical Rheumatology

Volumn 27, Issue 4, 2008, Pages 533-535

  Sabugo, Francisca ^a   Liberman, Claudio ^a   Niedmann, Juan Pablo ^b   Soto, Lilian ^a   Cuchacovich, Miguel ^a,c  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b Alemana Clinic   (Chile)

^c CLÍNICA LAS CONDES   (Chile)

Author keywords

SAPHO syndrome; Thyroidal function; TNF blocker

Indexed keywords

DOXYCYCLINE; INFLIXIMAB; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; RADIOACTIVE IODINE; THYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ECHOGRAPHY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUSTULE; REMISSION; SAPHO SYNDROME; SKIN MANIFESTATION; SYMPTOM; TREATMENT DURATION;

ACQUIRED HYPEROSTOSIS SYNDROME; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOTHYROIDISM; MALE; REMISSION INDUCTION; THYROXINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40949113276     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0767-y     Document Type: Article

References (15)

1. Hayem G, Bouchaaud-Cahbot A, Benali K et al (1999) SAPHO syndrome: A longterm follow-up study of 120 cases. Semin Arthritis Rheum 29:159-171
2. Wagner AD, Andresen J, Jendro MC et al (2002) Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46:1965-1968
3. Iqbal M, Kolodney M (2005) Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 52(Suppl 1):S118-120
4. Olivieri I, Padula A, Ciancio G et al (2003) Persistent efficacy of tumor necrosis factor alpha blockage therapy in SAPHO syndrome: Comment on the article by Wagner et al. Arthritis Rheum 48:1467-1468
5. Olivieri I, Padula A, Ciancio G et al (2002) Successful treatment of SAPHO syndrome with infliximab: Report of two cases. Ann Rheum Dis 61:375-376
6. Massara A, Cavazzini PL, Trotta F (2006) In SAPHO syndrome anti-TNF-therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45:730-733
7. Roux CH, Brocq O, Leccia N et al (2007) New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect? J Rheumatol 34:434-437
8. Dutz JP (2007) Tumor necrosis factor-α inhibition and palmoplantar pustulosis: Janus-faced therapy? J Rheumatol 34:247-249
9. Alvaro-Gracia JM, Yu C, Zvaifler NJ et al (1993) Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on fibroblast-like synoviocytes: Paradoxical induction of IFN-gamma and TNF-alpha receptor expression. J Clin Immunol 13:212-218
10. Pang XP, Hershman JM, Chung M et al (1989) Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125:1783-1788
11. Bartalena L, Bogazzi F, Brogioni S et al (1998) Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur J Endocrinol 138:603-614
12. Tang KT, Braverman LE, DeVito WJ (1995) Tumor necrosis factor-alpha and interferon-gamma modulate gene expression of type I 5′-deiodinase, thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. Endocrinology 136:881-888
13. Diez JJ, Hernanz A, Medina S et al (2002) Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol Oxford 57:515-521
14. Miyakoshi H, Ohsawa K, Yokoyama H et al (1992) Exacerbation of hypothyroidism following tumor necrosis factor-alpha infusion. Intern Med 31:200-203
15. Jones BM, Kwok CC, Kung AW (1999) Effect of radioactive iodine therapy on cytokine production in Graves' disease: Transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor-alpha, with longer term increases in interferon-gamma production. J Clin Endocrinol Metab 84:4106-4110